Rationale for randomised trials of prostate cancer screening

被引:0
作者
Alexander, FE [1 ]
Andriole, GL [1 ]
Aus, G [1 ]
Auvinen, A [1 ]
Beensterboer, P [1 ]
Blijenberg, BG [1 ]
Bonardi, R [1 ]
Buys, S [1 ]
Candas, B [1 ]
Ciatto, S [1 ]
Crawford, ED [1 ]
Demers, R [1 ]
de Koning, HJ [1 ]
Denis, L [1 ]
Dijk, MA [1 ]
Figueiredo, F [1 ]
Gellman, EP [1 ]
Gohagan, J [1 ]
Hakama, M [1 ]
Hugosson, J [1 ]
Kirkels, WI [1 ]
Kranse, R [1 ]
van der Kwast, TH [1 ]
Lilja, H [1 ]
Määttänen, L [1 ]
Mandel, J [1 ]
Miller, AB [1 ]
Monteiro, H [1 ]
Nelen, V [1 ]
Oberman, A [1 ]
Paez, A [1 ]
Prorok, PC [1 ]
Reding, D [1 ]
Rietbergen, JWBW [1 ]
Rose, DB [1 ]
Sanchez, AB [1 ]
Schröder, FH [1 ]
da Silva, EC [1 ]
Simpson, N [1 ]
Smith, PH [1 ]
Stadaert, B [1 ]
Stenman, UH [1 ]
Teppo, L [1 ]
Turkes, A [1 ]
Weissfeld, JL [1 ]
Yokochi, L [1 ]
机构
[1] Int Agcy Res Canc, F-69372 Lyon 08, France
关键词
prostate cancer; prostate specific antigen (PSA); screening; randomised controlled trials;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Screening for prostate cancer has been advocated by a number of organisations largely because there is good evidence that administration of the test for prostate specific antigen (PSA) results in the detection of cancers at an early stage. However, the mere fact that a cancer can be detected earlier in its natural history by screening is no guarantee that benefit will follow. Further, screening for prostate cancer can substantially impair the quality of life of those with detected and treated cancer, that would not otherwise have reduced Life expectancy. The only established mechanism to evaluate the efficacy of screening is the randomised controlled trial. In this paper we review the trials contributing to our collaboration, the advantages that will flow from them, and the reasons why decisions on the introduction of population-based screening for prostate cancer cannot be made before these trials have come to fruition. (C) 1999 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:262 / 271
页数:10
相关论文
共 13 条
[1]   ETHICS OF A PROSTATE-CANCER SCREENING TRIAL [J].
ADAMI, HO ;
BARON, JA ;
ROTHMAN, KJ .
LANCET, 1994, 343 (8903) :958-960
[2]  
Auvinen A, 1996, J Med Screen, V3, P97
[3]  
BOYLE P, 1998, AM SOC CLIN ONC ANN
[4]   Early prostate cancer - To treat or not to treat? [J].
Dearnaley, DP ;
Melia, J .
LANCET, 1997, 349 (9056) :892-893
[5]   A PROSPECTIVE EVALUATION OF PLASMA PROSTATE-SPECIFIC ANTIGEN FOR DETECTION OF PROSTATIC-CANCER [J].
GANN, PH ;
HENNEKENS, CH ;
STAMPFER, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 273 (04) :289-294
[6]   Comparison of pathologic characteristics of T1c and non-T1c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer [J].
Hoedemaeker, RF ;
Rietbergen, JBW ;
Kranse, R ;
van der Kwast, TH ;
Schroder, FH .
WORLD JOURNAL OF UROLOGY, 1997, 15 (06) :339-345
[7]   Fifteen-year survival in prostate cancer - A prospective, population-based study in Sweden [J].
Johansson, JE ;
Holmberg, L ;
Johansson, S ;
Bergstrom, R ;
Adami, HO .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (06) :467-471
[8]  
KRAHN MD, 1994, JAMA-J AM MED ASSOC, V272, P781
[9]  
LABRIE F, 1998, AM SOC CLIN ONC ANN
[10]   Population-based study of long-term survival in patients with clinically localised prostate cancer [J].
LuYao, GL ;
Yao, SL .
LANCET, 1997, 349 (9056) :906-910